Company: HRTX
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0000950170-25-028374
Chunk: 33

Company: HERON THERAPEUTICS, INC. /DE/
Filing Date: 2025-02-27
Form: 10-K
Item: Item 1A
Chunk 33
---
 expense and limit our ability to commercialize our Products. In addition, any failure to comply with these regulations could result in substantial fines or penalties.  

•We may incur significant liability if it is determined that we are promoting the “off-label” use of drugs or promoting in a non-truthful and misleading way.  

•Health care reform could increase our expenses and adversely affect the commercial success of our Products.  

•Our use of hazardous materials could subject us to liabilities, fines and sanctions. 

•Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a negative impact on our business. 

•We are and may become subject to stringent and evolving laws, regulations, rules, contractual obligations, policies and other obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions, litigation, fines and penalties, disruptions of our business operations, reputational harm, loss of revenue or profits, and other adverse business consequences. 

•Security breaches and other disruptions could compromise our information and expose us to liability, which would cause our business and reputation to suffer.  

•Changes in government policies, laws, and regulations and with respect to the government workforce may have a negative impact on our business and the markets in which we operate. 

•If we are unable to adequately protect or enforce our intellectual property rights, we may lose valuable assets or incur costly litigation to protect our rights.  

•We may be subject to claims that we have infringed on the intellectual property rights of others, and any litigation could force us to stop developing or selling potential products and could be costly, divert management attention and harm our business.  

19

•We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers. 

•The price of our common stock has been and may continue to be volatile. 

•Our certificate of incorporation, our bylaws and Delaware law contain provisions that could discourage another company from acquiring us and may prevent attempts by our stockholders to replace or remove our current management. 

•Future utilization of net operating loss carryforwards or research and development credit carryforwards may be impaired due to recent changes in ownership. 

•Actions of activist stockholders could impact the pursuit of our business strategies, cause us to incur substantial costs, divert our management’s attention and resources, and adversely affect our business, results of operations, liquidity, financial condition, and the trading price of